Takeda takes pole position in norovirus vaccine development

Cruise ships, take heart. Takeda Pharmaceuticals is leading the efforts to develop a vaccine against norovirus, the vomiting bug that has crippled pleasure ships and afflicted schools. If Takeda beats its rivals to the market, the vaccine could add $400 million to its sales.  Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.